Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX, USA.
Department of Hematology, Peking University International Hospital, Zhong-Guan-Cun Life Science Park Road, Beijing, China.
BMC Cancer. 2021 Dec 8;21(1):1315. doi: 10.1186/s12885-021-09061-3.
Flow cytometry (FC) is a popular method to detect bone marrow (BM) involvement in patients with B-cell non-Hodgkin lymphoma (B-NHL). The majority of screen panels of FC still rely on finding monoclonal B-cells, e.g., B-cells with immunoglobin (Ig) light-chain restriction, which has many limitations. Therefore, exploring new markers is warranted.
A total of 52 cases of B-NHL with BM involvement were collected. The median age was 60 years. Out of these 52 cases, 34 were male, and 18 were female. A 10-color FC panel was used to detect the expression of CD54 on lymphoma cells. The expression of CD54 was calculated as the mean fluorescence index ratio (MFIR) and was described as the mean ± standard error of the mean (SEM).
Up to 18/52 (34.62%) of BM specimens abnormally expressed an increased level of CD54, including 1/10 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 9/13 cases of mantle cell lymphoma (MCL), 2/14 cases of follicular lymphoma (FL), 5/9 cases of marginal zone lymphoma (MZL), and 1/3 cases of high-grade B-NHL (HG B-NHL). The expression level of CD54 was significantly increased in MCL cases (53.41 ± 11.04) compared with CLL/SLL cases (11.66 ± 2.79) and FL cases (13.49 ± 2.81). The lowest percentage of CD54-positive B-cells attained 0.13%. In 5/9 cases of MZL and 1/3 cases of HG B-NHL, increased expression of CD54 was the only abnormal immunophenotype detected besides Ig light-chain restriction. No aberrant CD54 expression was identified by FC in lymphoplasmacytic lymphoma (LPL) (0/2) and Burkitt lymphoma (BL) (0/1) cases. Aberrant expression of CD54 was not related to plasma cell differentiation.
Lymphoma cells, especially in MCL and MZL cases, frequently show increased expression of CD54. Such aberrant expression is not related to plasma cell differentiation. We highly recommend adding CD54 to the FC screening panel to detect BM involvement in patients with B-NHL.
流式细胞术（FC）是一种常用于检测 B 细胞非霍奇金淋巴瘤（B-NHL）患者骨髓（BM）受累的方法。大多数 FC 筛选面板仍依赖于寻找单克隆 B 细胞，例如免疫球蛋白（Ig）轻链受限的 B 细胞，这存在许多局限性。因此，有必要探索新的标志物。
共收集 52 例 BM 受累的 B-NHL 病例。中位年龄为 60 岁。其中 34 例为男性，18 例为女性。使用 10 色 FC 面板检测淋巴瘤细胞表面 CD54 的表达。CD54 的表达以平均荧光指数比（MFIR）计算，并以平均值±标准误差（SEM）表示。
多达 18/52（34.62%）的 BM 标本异常表达高水平的 CD54，包括 1/10 例慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）、9/13 例套细胞淋巴瘤（MCL）、2/14 例滤泡淋巴瘤（FL）、5/9 例边缘区淋巴瘤（MZL）和 1/3 例高级别 B-NHL（HG B-NHL）。MCL 病例的 CD54 表达水平显著高于 CLL/SLL 病例（53.41±11.04）和 FL 病例（13.49±2.81）。CD54 阳性 B 细胞的最低百分比达到 0.13%。在 5/9 例 MZL 和 1/3 例 HG B-NHL 病例中，除 Ig 轻链受限外，仅检测到 CD54 表达异常的免疫表型。在淋巴浆细胞淋巴瘤（LPL）（0/2）和伯基特淋巴瘤（BL）（0/1）病例中，FC 未检测到异常的 CD54 表达。CD54 的异常表达与浆细胞分化无关。
淋巴瘤细胞，特别是在 MCL 和 MZL 病例中，常表现出 CD54 表达增加。这种异常表达与浆细胞分化无关。我们强烈建议在 FC 筛选面板中添加 CD54，以检测 B-NHL 患者的 BM 受累情况。
